Home
Olav Mella's picture

Olav Mella

Guest Researcher
  • E-mailolav.mella@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2022). No replication of previously reported association with genetic variants in the T cell receptor alpha (TRA) locus for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Translational Psychiatry.
  • Show author(s) (2022). Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal Adenocarcinomas. Cancers. 1-15.
  • Show author(s) (2022). Genetic association study in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci. Brain, Behavior, and Immunity. 362-369.
  • Show author(s) (2022). Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients. PLOS ONE. 1-21.
  • Show author(s) (2021). Reduced Endothelial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Results From Open-Label Cyclophosphamide Intervention Study. Frontiers in medicine.
  • Show author(s) (2021). Fine mapping of the major histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suggests involvement of both HLA class I and class II loci. Brain, Behavior, and Immunity. 101-109.
  • Show author(s) (2021). A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. JCI Insight. 1-19.
  • Show author(s) (2020). Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. Frontiers in medicine. 1-15.
  • Show author(s) (2020). Human Leukocyte Antigen Alleles Associated With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Scientific Reports. 1-8.
  • Show author(s) (2019). B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 585-593.
  • Show author(s) (2018). Rituximab serum concentrations and anti-rituximab antibodies during B-cell depletion therapy for myalgic encephalopathy/chronic fatigue syndrome. Clinical Therapeutics. 9.
  • Show author(s) (2018). Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Molecular Neurobiology. 1-9.
  • Show author(s) (2018). Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncology. 483-492.
  • Show author(s) (2017). Consolidative radiotherapy to residual masses after chemotherapy is associated with improved outcome in diffuse large B-cell lymphoma. A retrospective, population-based study. Clinical Lymphoma, Myeloma & Leukemia. 125-135.
  • Show author(s) (2016). Serum BAFF and APRIL levels, T-lymphocyte subsets, and immunoglobulins after B-cell depletion using the monoclonal anti-CD20 antibody rituximab in myalgic encephalopathy/chronic fatigue syndrome. PLOS ONE.
  • Show author(s) (2016). Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight.
  • Show author(s) (2016). Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain, Behavior, and Immunity. 32-39.
  • Show author(s) (2015). B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. PLOS ONE.
  • Show author(s) (2013). Early rehabilitation of cancer patients - a randomized controlled intervention study. BMC Cancer. 7 pages.
  • Show author(s) (2012). Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update. International Journal of Hyperthermia. 549-553.
  • Show author(s) (2011). Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLOS ONE. 13 pages.
  • Show author(s) (2009). cDNA microarray analysis of serially sampled cervical cancer specimens from patients treated with thermochemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics. 1562-1569.
  • Show author(s) (2009). Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicenter randomized trial by The European Society for Hyperthermic Oncology. International Journal of Hyperthermia. 323-334.
  • Show author(s) (2009). Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurology. 7 pages.
  • Show author(s) (2009). CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989-2003. American Journal of Neuroradiology. 744-751.
  • Show author(s) (2008). Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 435-442.
  • Show author(s) (2008). AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003. BMC Cancer. 8 pages.
  • Show author(s) (2004). Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway. Supportive Care in Cancer. 312-318.
  • Show author(s) (2004). Tilbud om komplementærbehandling i sykehus. Tidsskrift for Den norske legeforening. 3078-3080.
  • Show author(s) (2004). Tilbud om komplementær behandling i sykehus? Tidsskrift for Den norske legeforening. 3078-3080.
  • Show author(s) (2004). Pigmented astrocytoma with suprasellar location: case report and literature review. Acta Neuropathologica. 461-466.
  • Show author(s) (2004). Knowledge of and attitudes toward complementary and alternative therapies: a national multicentre study of oncology professionals in Norway. European Journal of Cancer. 529-535.
  • Show author(s) (2004). Incidence, Clinical Features, Treatment and Outcome of Primary Central Nervous System Lymphoma in Norway. Acta Oncologica. 520-529.
  • Show author(s) (2003). Skal alternative utøvere behandle kreft - hva mener onkologiske helsearbeidere? Tidsskrift for Den norske legeforening. 3059-3061.
  • Show author(s) (2003). Should alternative therapists treat cancer-what is the opinion of oncology health personnel? Tidsskrift for Den norske legeforening. 3059-3061.
  • Show author(s) (2003). CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 3840-3848.
  • Show author(s) (2002). Norwegian Oncologists' Expectations of Intensity-modulated Radiotherapy. Acta Oncologica. 562-565.
  • Show author(s) (2001). Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiotherapy and Oncology. 313-320.
  • Show author(s) (2001). High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment. 111-116.
  • Show author(s) (2001). Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiotherapy and Oncology. 147-154.
  • Show author(s) (2000). The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 645-652.
  • Show author(s) (2000). The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 645-652.
  • Show author(s) (1999). Status of clinical hyperthermia. Acta Oncologica. 863-873.
  • Show author(s) (1998). Kinetics of total plasma homocysteine during basal conditions. Clinical Chemistry. 1886-1891.
  • Show author(s) (1998). Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • Show author(s) (1998). Intravenous infusion of glucose and the vasodilator sodium nitroprusside in combination with local hyperthermia: Effects on tumour pH and tumour re in the BT4An rat tumour model. International Journal of Hyperthermia. 403-416.
  • Show author(s) (1998). Intravenous infusion of glucose and the vasodilator sodium nitroprusside in combinaiton with local hyperthermia: Effects on tumour pH and tumour response in the BT(4)AN rat tumour model. International Journal of Hyperthermia. 403-416.
  • Show author(s) (1997). Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomized double-blind, the "nordic" phase III st. British Journal of Cancer. 270-277.
  • Show author(s) (1996). Use of the vasodilator sodium nitroprusside during local hyperthermia: Effects on tumor temperature and tumor response in a rat tumor model. International Journal of Radiation Oncology, Biology, Physics. 403-415.
  • Show author(s) (1996). Høydosebehandling med autolog stamcellestøtte ved maligne lidelser. Tidsskrift for Den norske legeforening. 2577-81.
  • Show author(s) (1996). Høydosebehandling med autolog stamcellestøtte ved maligne lidelser. Tidsskrift for Den norske legeforening. 2577-2281.
  • Show author(s) (1996). Effect of sodium nitroprusside-induced hypotension on the blood flow in subcutaneous and intramuscular BT4AN tumors and normal tissues in rats. International Journal of Radiation Oncology, Biology, Physics. 393-401.
  • Show author(s) (1996). Effect of sodium nitroprusside-induced hypotension on the blood flow in subcutaneous and intramuscular BT(4)AN tumors and normal tissues in rats. International Journal of Radiation Oncology, Biology, Physics. 393-401.
  • Show author(s) (1996). ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease. Acta Oncologica. 73-80.
  • Show author(s) (1995). Timing of hypertonic glucose and thermochemotherapy in the BT%eAn rat glioma: Relation to intratumoral pH reduction and circulatory changes after glucose supply. International Journal of Radiation Oncology, Biology, Physics. 409-416.
  • Show author(s) (1995). Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. The Lancet. 540-543.
  • Show author(s) (1995). Hypertermi: Biologi - Fysik - Klinik. Helsetjenesten/Medisinsk teknikk. 21-27.
Report
  • Show author(s) (1995). Høydosebehandling med autolog stamcellestøtte ved maligne lidelser. Instilling fra rådgivende gruppe nedsatt av Helsedirektoratet, senere Statens Helsetilsyn. .
Academic lecture
  • Show author(s) (2014). “The prevalence of distress, emotional reactivity, fatigue and health related quality of life among newly diagnosed cancer patients starting adjuvant treatment”.
  • Show author(s) (2003). Trimodality treatment with regional hyperthermia, radiotherapy and chemotherapy in primary inoperable or recurrent rectal carcinoma.
  • Show author(s) (2003). Trimodality treatment of inoperable/locally recurrent rectal cancer with hyperthermia, radiotherapy and chemotherapy. Pilot studies.
  • Show author(s) (2003). Regional hyperthermia in addition to chemoradiotherapy in cervical carcinoma: Results of a phase II study.
  • Show author(s) (2003). Regional hyperthermia in addition to chemoradiotherapy in cervical cancer: results of a phase II-study.
  • Show author(s) (2003). Regional hyperthermia added to chemoradiotherapy in advanced cervical cancer: Multicenter international feasibility.
Reader opinion piece
  • Show author(s) (2018). Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon . Tidsskrift for Den norske legeforening. 12-13.
  • Show author(s) (2017). Mer om pyruvat dehydrogenase og kronisk utmattelsessyndrom. Tidsskrift for Den norske legeforening.
  • Show author(s) (2017). Chronic fatigue syndrome and pyruvate dehydrogenase function. Tidsskrift for Den norske legeforening.
  • Show author(s) (2002). Hyperthermia alone or combined with cisplatin in addition to radiotherapy for advanced uterine cervical cancer. International Journal of Hyperthermia. 25-30.
Academic commentary
  • Show author(s) (2018). Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon.
Non-fiction book
  • Show author(s) (1999). Cytostatika Medikamentell kreftbehandling kap. 8 Kvalme og oppkast ved cytostatikabehandling. Institutt for farmakoterapi og Den Norske Kreftforening.
Feature article
  • Show author(s) (1997). Når ansvarsfraskrivelse blir arbeidsform. [Kronikk]. Aftenposten (morgenutg. : trykt utg.).
  • Show author(s) (1997). Fremtidens kreftbehandling. [Kronikk]. Bergens Tidende.
  • Show author(s) (1996). Dagbladet på ville veier. Dagbladet. 3.
Doctoral dissertation
  • Show author(s) (1990). Optimization of hyperthemia and chemotherapy in an experi- mental brain tumour model.
Academic chapter/article/Conference paper
  • Show author(s) (2009). Myelomatose. 11 pages.
  • Show author(s) (1999). Myelomatose. 5 pages.
  • Show author(s) (1999). Kvalme og oppkast ved cytostaticabehandling. 8 pages.
Abstract
  • Show author(s) (2014). Particle therapy in Norway - report from the national project group. Radiotherapy and Oncology. 314-314.
Poster
  • Show author(s) (2003). Regional hyperthermia added to chemoradiotherapy in advanced cervical cancer: Multicenter international feasibility.
  • Show author(s) (2001). Regional Hyperthermia as part of trimodality treatment of locally advanced/locally recurrent cervical carcinoma, and primarily inoperable/locally recurrent carcinoma.
  • Show author(s) (2001). National survey of IMRT expectations in Norway.
Academic literature review
  • Show author(s) (2021). Pathomechanisms and possible interventions in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Journal of Clinical Investigation.

More information in national current research information system (CRIStin)